Letter to the Editor

Split Viewer

Blood Res 2014; 49(1):

Published online March 31, 2014

https://doi.org/10.5045/br.2014.49.1.72

© The Korean Society of Hematology

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload

Samin Alavi1*, Elham Sadeghi2, and Azin Ashenagar1

1Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2Thalassemia Comprehensive Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Correspondence to : Samin Alavi. Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, Iran. s.alavi@sbmu.ac.ir

Received: January 2, 2014; Revised: February 20, 2014; Accepted: March 4, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

REFERENCES

  1. Belhoul, KM, Bakir, ML, Kadhim, AM, Dewedar, HE, Eldin, MS, Alkhaja, FA. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med, 2013;33;18-21.
    Pubmed
  2. Kwiatkowski, JL. Management of transfusional iron overload differential - properties and efficacy of iron chelating agents. J Blood Med, 2011;2;135-149.
    Pubmed
  3. Chhim, RF, Shelton, CM, Christensen, ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther, 2013;18;14-38.
    Pubmed
  4. Galanello, R, Agus, A, Campus, S, Danjou, F, Giardina, PJ, Grady, RW. Combined iron chelation therapy. Ann N Y Acad Sci, 2010;1202;79-86.
    Pubmed
  5. Viprakasit, V, Nuchprayoon, I, Chuansumrit, A, et al. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol, 2013;88;251-260.
    Pubmed
  6. Farmaki, K, Tzoumari, I, Pappa, C, Chouliaras, G, Berdoukas, V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol, 2010;148;466-475.
    Pubmed
  7. Porter, JB, Wood, J, Olivieri, N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson, 2013;15;38.
    Pubmed
  8. Pennell, DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci, 2005;1054;373-378.
    Pubmed
  9. Balocco, M, Carrara, P, Pinto, V, Forni, GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol, 2010;85;460-461.
    Pubmed
  10. Voskaridou, E, Christoulas, D, Terpos, E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol, 2011;154;654-656.
    Pubmed

Article

Letter to the Editor

Blood Res 2014; 49(1): 72-73

Published online March 31, 2014 https://doi.org/10.5045/br.2014.49.1.72

Copyright © The Korean Society of Hematology.

Efficacy and safety of combined oral iron chelation therapy with deferasirox and deferiprone in a patient with beta-thalassemia major and persistent iron overload

Samin Alavi1*, Elham Sadeghi2, and Azin Ashenagar1

1Pediatric Congenital Hematologic Disorders Research Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2Thalassemia Comprehensive Center, Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Correspondence to: Samin Alavi. Mofid Children's Hospital, Shahid Beheshti University of Medical Sciences, Tehran 15468-15514, Iran. s.alavi@sbmu.ac.ir

Received: January 2, 2014; Revised: February 20, 2014; Accepted: March 4, 2014

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

    References

    1. Belhoul, KM, Bakir, ML, Kadhim, AM, Dewedar, HE, Eldin, MS, Alkhaja, FA. Prevalence of iron overload complications among patients with b-thalassemia major treated at Dubai Thalassemia Centre. Ann Saudi Med, 2013;33;18-21.
      Pubmed
    2. Kwiatkowski, JL. Management of transfusional iron overload differential - properties and efficacy of iron chelating agents. J Blood Med, 2011;2;135-149.
      Pubmed
    3. Chhim, RF, Shelton, CM, Christensen, ML. Recent new drug approvals, part 2: drugs undergoing active clinical studies in children. J Pediatr Pharmacol Ther, 2013;18;14-38.
      Pubmed
    4. Galanello, R, Agus, A, Campus, S, Danjou, F, Giardina, PJ, Grady, RW. Combined iron chelation therapy. Ann N Y Acad Sci, 2010;1202;79-86.
      Pubmed
    5. Viprakasit, V, Nuchprayoon, I, Chuansumrit, A, et al. Deferiprone (GPO-L-ONE(®)) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol, 2013;88;251-260.
      Pubmed
    6. Farmaki, K, Tzoumari, I, Pappa, C, Chouliaras, G, Berdoukas, V. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol, 2010;148;466-475.
      Pubmed
    7. Porter, JB, Wood, J, Olivieri, N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson, 2013;15;38.
      Pubmed
    8. Pennell, DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci, 2005;1054;373-378.
      Pubmed
    9. Balocco, M, Carrara, P, Pinto, V, Forni, GL. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Am J Hematol, 2010;85;460-461.
      Pubmed
    10. Voskaridou, E, Christoulas, D, Terpos, E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol, 2011;154;654-656.
      Pubmed
    Blood Res
    Volume 59 2024

    Stats or Metrics

    Share this article on

    • line

    Blood Research

    pISSN 2287-979X
    eISSN 2288-0011
    qr-code Download